Xencor, Inc.
NASDAQ:XNCRBiotechnology
-$0.13 today
- Market cap
- $2.55B
- Beta
- 0.93
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$2.29
Volume 1.09M
Average 0.80M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Xencor, Inc.
NASDAQ:XNCR
Intrinsic Alpha fair value
Locked
Current Price
$34.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -8.6% | +28.1% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -8.6% over three years. Forward estimates point to Revenue at +28.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Genmab A/S NASDAQ:GMAB | $31.67B | $51.37 | Not rated | 18.7 | +67.98% |
Celldex Therapeutics, Inc. NASDAQ:CLDX | $2.26B | $28.83 | Not rated | -7.8 | +12.20% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | $15.48 | Undervalued | -6.4 | -5.09% |
Immunocore Holdings plc NASDAQ:IMCR | $1.55B | $29.94 | Not rated | -77.5 | -31.10% |
Nektar Therapeutics NASDAQ:NKTR | $1.07B | $37.27 | Not rated | -9.3 | -46.08% |
Compugen Ltd. NASDAQ:CGEN | $198.92M | $2.10 | Undervalued | 5.4 | +17.50% |
Innate Pharma S.A. NASDAQ:IPHA | $154.15M | $1.38 | Not rated | -3.0 | -47.49% |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | $2.20 | Not rated | -3.6 | +39.44% |
Adagene Inc. NASDAQ:ADAG | $64.38M | $1.71 | Not rated | -7.9 | +11.05% |
Immutep Limited NASDAQ:IMMP | $25.64M | $3.48 | Not rated | -0.9 | -78.17% |
Continue the stock analysis
Jump to another research area for this company.